This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2022 Oct 13;140(15):1657-1658.

doi: 10.1182/blood.2022018005.

By any other name …

Mark Levis¹

Affiliations

PMID: 36227747
DOI: 10.1182/blood.2022018005

Free article

Comment

By any other name …

Mark Levis. Blood. 2022.

Free article

. 2022 Oct 13;140(15):1657-1658.

doi: 10.1182/blood.2022018005.

Author

Mark Levis¹

Affiliation

¹ Johns Hopkins University.

PMID: 36227747
DOI: 10.1182/blood.2022018005

No abstract available

PubMed Disclaimer

Comment on

Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine.
Döhner H, Wei AH, Roboz GJ, Montesinos P, Thol FR, Ravandi F, Dombret H, Porkka K, Sandhu I, Skikne B, See WL, Ugidos M, Risueño A, Chan ET, Thakurta A, Beach CL, Lopes de Menezes D. Döhner H, et al. Blood. 2022 Oct 13;140(15):1674-1685. doi: 10.1182/blood.2022016293. Blood. 2022. PMID: 35960871 Free PMC article. Clinical Trial.

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
- Silverchair Information Systems